Loading...
Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $9.7K Total Trade · DGFT Verified
Rutva Medicare is an Indian pharmaceutical exporter with a total trade value of $9.7K across 3 products in 3 therapeutic categories. Based on 27 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Liraglutide ($4.4K), Etanercept ($3.9K), Ribavirin ($1.4K).
Rutva Medicare, established in 2021, is a professionally managed pharmaceutical exporter based in Surat, Gujarat, India. The company specializes in supplying and exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products are sourced from well-known and certified manufacturers, ensuring high-quality standards. Rutva Medicare operates under the Goods and Services Tax (GST) number 24AZMPA5662R1ZT.
The company's registered office is located at Shop No. 216, 2nd Floor, Amazing Star, Opp. Vishwamitri Soc., Yogi Chowk, Surat, Gujarat - 395006, India. Rutva Medicare is a privately held entity, with ownership details not publicly disclosed. The company has an annual turnover of approximately below ₹0.5 Crore and employs fewer than 20 individuals.
Rutva Medicare operates across 3 therapeutic categories, with Diabetes & Endocrine (45.6%), Biologics & Immunotherapy (40.1%), Antivirals (14.3%) representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Diabetes & Endocrine
1 products · 45.6% · $4.4K
Biologics & Immunotherapy
1 products · 40.1% · $3.9K
Antivirals
1 products · 14.3% · $1.4K
Rutva Medicare exports 3 pharmaceutical products across 3 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Liraglutide | Diabetes & Endocrine | $4.4K | 7 | 0.1% | 10 |
| 2 | Etanercept |
Headquarters, ownership, manufacturing facilities, and key leadership
Rutva Medicare, established in 2021, is a professionally managed pharmaceutical exporter based in Surat, Gujarat, India. The company specializes in supplying and exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. These products are sourced from well-known and certified manufacturers, ensuring high-quality standards. Rutva Medicare operates under the Goods and Services Tax (GST) number 24AZMPA5662R1ZT.
The company's registered office is located at Shop No. 216, 2nd Floor, Amazing Star, Opp. Vishwamitri Soc., Yogi Chowk, Surat, Gujarat - 395006, India. Rutva Medicare is a privately held entity, with ownership details not publicly disclosed. The company has an annual turnover of approximately below ₹0.5 Crore and employs fewer than 20 individuals.
Rutva Medicare does not own manufacturing facilities; instead, it collaborates with certified vendors and manufacturers to source its pharmaceutical products. This strategy allows the company to offer a diverse range of high-quality formulations without the overhead associated with maintaining its own production facilities. The specific locations and capacities of these partner manufacturers are not publicly disclosed.
| $3.9K |
| 8 |
0.0% |
| 8 |
| 3 | Ribavirin | Antivirals | $1.4K | 12 | 0.2% | 9 |
Rutva Medicare exports 3 pharmaceutical products across 3 therapeutic categories with a total export value of $9.7K. The top category is Diabetes & Endocrine (45.6% of portfolio), followed by Biologics & Immunotherapy (40.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
The leadership team of Rutva Medicare includes:
Detailed information about other executives, such as the CEO, CFO, and other key personnel, is not publicly available.
Regulated market presence, emerging market penetration, and geographic strategy
Rutva Medicare's export activities are primarily focused on Uganda, with 100% of its shipments directed to this market. There is no publicly available information regarding the company's presence or regulatory approvals in other regulated markets such as the United States, European Union, United Kingdom, Australia, or Japan.
Rutva Medicare's export activities are primarily focused on Uganda, with 100% of its shipments directed to this market. There is no publicly available information regarding the company's penetration into other emerging markets in Africa, Latin America, or Southeast Asia.
Rutva Medicare's export strategy is currently concentrated in Uganda, indicating a focused approach in a single market. This concentration may expose the company to risks associated with overdependence on one market, such as economic fluctuations or regulatory changes in Uganda. Diversifying into additional markets could mitigate these risks and provide growth opportunities.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
There is no publicly available information regarding Rutva Medicare's facility registrations with the U.S. Food and Drug Administration (FDA), approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. This suggests that the company may not currently have a presence in the U.S. market or has not pursued FDA approvals for its products.
Rutva Medicare's products are sourced from certified manufacturers; however, there is no publicly available information confirming whether these manufacturers hold World Health Organization (WHO) prequalification or European Union Good Manufacturing Practice (EU GMP) certificates. This lack of certification may limit the company's ability to access certain international markets that require such credentials.
Rutva Medicare operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds a valid GST registration, indicating compliance with Indian tax regulations. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs) are not publicly disclosed.
There is no publicly available information regarding any Form 483 observations, warning letters, or import alerts issued to Rutva Medicare. This absence suggests that the company has not faced significant regulatory challenges in its operations.
Market share comparison, key differentiators, and strategic analysis
Rutva Medicare operates in the competitive pharmaceutical export market, with numerous companies offering similar products. However, specific information regarding the company's top competitors, market share comparisons, or head-to-head analyses is not publicly available. The company's focus on a single market (Uganda) may limit its exposure to broader competitive dynamics.
Rutva Medicare's key differentiators include its focus on supplying high-quality finished pharmaceutical formulations sourced from certified manufacturers. The company's ability to offer a diverse product range without owning manufacturing facilities allows for flexibility and responsiveness to market demands. However, the lack of publicly available information on certifications such as WHO prequalification or EU GMP may limit its appeal in certain international markets.
Rutva Medicare's current strategic direction appears to be focused on exporting pharmaceutical products to Uganda. The company's future outlook would benefit from diversifying its market presence to reduce dependency on a single market and to leverage growth opportunities in other regions.
Track record assessment, certifications to verify, and pre-order checks
Rutva Medicare sources its products from well-known and certified manufacturers, ensuring high-quality standards. However, specific details regarding the track record, export volume, consistency, and reliability of these suppliers are not publicly available. The company's focus on a single market (Uganda) may limit its exposure to broader supplier dynamics.
Importers should verify the following certifications when considering products from Rutva Medicare:
To verify these certifications, importers can request copies of the certificates directly from Rutva Medicare or its suppliers. Additionally, they can consult the official websites of the certifying bodies or contact them directly for verification.
When conducting due diligence on Rutva Medicare, importers should consider the following steps:
Red flags to watch for include a lack of verifiable certifications, inconsistent product quality, and unresolved regulatory issues. Recommended pre-order checks include requesting product samples, conducting quality audits, and verifying the company's compliance with international standards.
Rutva Medicare exports 3 pharmaceutical products across 3 therapeutic categories. The top exports are Liraglutide ($4.4K), Etanercept ($3.9K), Ribavirin ($1.4K). Total export value is $9.7K.
Rutva Medicare's total pharmaceutical export value is $9.7K, based on 27 verified shipments recorded in Indian Customs (DGFT) data.
Rutva Medicare exports across 3 therapeutic categories. The largest are Diabetes & Endocrine (45.6%, 1 products), Biologics & Immunotherapy (40.1%, 1 products), Antivirals (14.3%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Products Tracked
3 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.